UPDATE: Bank Of America Reiterates On Catalent On Operationally Solid F1Q

Loading...
Loading...
In a report published Friday, Bank of America analyst Derik de Bruin reiterated a Buy rating on
CatalentCTLT
, and raised the price target from $26.00 to $28.00. In the report, Bank of America noted, “F1Q revenues of $418mn (+1% y/y, +1% constant currency (‘CC')) were above our $406mn (-1.9% y/y, -1.5% CC) est. and the Street's $411mn. Adj. EBITDA was $83mn (+2% y/y; 19.9% margin), vs. our $79mn est. (19.4% margin), driven by driven by favorable product mix shifts in softgels (from Rx to OTC), modified release technologies (MRT), and clinical services. Adj. net income was $13.4mn, below our $21.5mn est., as the mandatory waiting period to use IPO proceeds delayed timing of debt paydown and increased interest expense. As a result, Adj. EPS were $0.13 vs. our/Street est. of $0.20. That said, CTLT is quickly deleveraging with Net Debt / Adj. EBITDA at 4.0x (vs. 6.1x at 6/30). Overall, CTLT's seasonally weaker F1Q was better than expected, and the reaffirmation of guidance despite mounting F/X headwinds was reassuring, suggesting better core growth.” Catalent closed on Thursday at $23.81.
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorPrice TargetAnalyst RatingsBank of AmericaDerik de Bruin
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...